Adrenal Crisis Market

DelveInsight’s ‘Adrenal Crisis—Market Insights, Epidemiology, and Market Forecast—2032’ report deliver an in-depth understanding of Adrenal Crisis, historical and forecasted epidemiology, as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

The Adrenal Crisis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Adrenal Crisis symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Adrenal Crisis symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Adrenal Crisis Understanding and Treatment Algorithm

Adrenal Crisis Overview

Adrenal crisis refers to overwhelming and life-threatening adrenal insufficiency. The most common signs of adrenal crisis is shock (very low blood pressure with a loss of consciousness), dehydration, and an imbalance of sodium and potassium levels in the body. In some cases, shock is preceded by fever, nausea, vomiting, abdominal pain, weakness or fatigue, and confusion. Adrenal crisis usually occurs after an infection, trauma, or another stressor.

 

Adrenal Crisis Diagnosis and Treatment

This section covers the details of diagnostic methods and conventional and current medical therapies available in the Adrenal Crisis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight Adrenal Crisis market report gives a holistic understanding of Adrenal Crisis clinical manifestations by including disease definition, symptoms, causes, risk factors, physiology, and diagnosis. It also provides Adrenal Crisis treatment algorithms and treatment guidelines in the US, Europe, and Japan.

 

The standard of care treatment for adrenal crisis is an instant infusion of hormone replacement drugs: hydrocortisone (an initial bolus of 100 mg IV or IM followed by 200 mg over 24 h or 50 mg IV or IM at every 6 h), 5% Dextrose containing solution (for Hypoglycemia), IV Sodium chloride 0.9% (in hypovolemia condition), and antibiotics (if the patient has persistent symptoms of infection). The main goal of these medications is to revive normal cortisol levels in the patient and stabilize them.

Adrenal Crisis Epidemiology

The Adrenal Crisis symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

 

Key Findings

The total prevalent cases of Adrenal Crisis patients in the 7MM are increasing during the study period, i.e., 2019–2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted Adrenal Crisis symptoms epidemiology segmented as the Total Diagnosed Prevalence, Gender-specific Cases, and Age-specific Cases. The report includes the prevalent cases scenario of the Adrenal Crisis in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Adrenal Crisis Epidemiology

The epidemiology segment also provides the Adrenal Crisis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total number of prevalent cases of Adrenal Crisis in 7MM countries was 130,175 in 2021.

Adrenal Crisis Drug Chapters

The Adrenal Crisis report’s drug chapter segment encloses the detailed analysis of Adrenal Crisis early-stage (Phase I, II, and III) pipeline drugs. It also helps understand the Adrenal Crisis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Adrenal Crisis Emerging Drugs

 

ATRS-1902: Antares Pharma

ATRS-1902 is an investigational rescue treatment that uses a proprietary autoinjector to deliver a stable liquid formulation of hydrocortisone.

 

Recently, the company announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support the advancement of the ATRS-1902 development program to a pivotal clinical study for treating acute adrenal insufficiency, known as an adrenal crisis, in adults and adolescents, using the Vai novel proprietary rescue pen platform to deliver a stable liquid formulation of hydrocortisone.

 

Zeneo: Eton Pharmaceuticals

Zeneo is a proprietary needleless device developed and manufactured by Crossject. The pre-filled, single-use device propels medication through the skin in less than a tenth of a second. The device’s compact form factor, simple two-step administration, and needle-free technology make it an ideal delivery system for emergency medications that need to be administered in stressful situations by non-healthcare professionals. Crossject holds more than 400 global patents on the device, including 24 issued in the United States that extend as far as 2037, and has completed bioequivalence and human factor studies with the Zeneo device using various medications.

 

Zeneo hydrocortisone is expected to be the first and only hydrocortisone autoinjector available for patients that require a rescue dose of hydrocortisone. Currently, injectable hydrocortisone is only available in the United States in a lyophilized powder formulation that must be reconstituted and manually delivered via a traditional syringe.

 

Eton expects to submit a New Drug Application for the product to the US Food and Drug Administration in 2023 and plans to request Orphan Drug Designation.

Other Products detailed in the report…

Adrenal Crisis Market Outlook

The report’s Adrenal Crisis market outlook helps understand the historic, current better, and forecasted Adrenal Crisis market trends by analyzing the impact of current therapies on the market, unmet needs, SWOT analysis, and demand for better technology.

 

This segment gives a holistic analysis of the Adrenal Crisis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

 

According to DelveInsight, the Adrenal Crisis market in 7MM is expected to grow steadily during the study period 2019–2032.

 

Various new therapies are in development, focusing on alleviating the limitations of the currently approved drugs. Some of the most prominent ones include ATRS-1902 (Antares Pharma), and Zeneo (Eton Pharmaceuticals), among others. The market is poised to take off with novel candidates like ATRS-1902 and regulators facilitating drug development with various designations, including Fast track Designation, Orphan Drug Designation, etc.,

 

Key Findings

This section includes a glimpse of the Adrenal Crisis market in 7MM.

 

Adrenal Crisis market size in the seven major markets was USD 11.5 million in 2021.

 

The United States Market Outlook

This section provides the total Adrenal Crisis market size and market size by therapies in the United States.

 

EU-5 Countries: Market Outlook

The total Adrenal Crisis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

The United States accounts for the largest market size for the Adrenal Crisis followed by Germany, France, Italy, the United Kingdom, and Spain.

 

Japan: Market Outlook

The total Adrenal Crisis market size and market size by therapies in Japan are provided in this section.

Adrenal Crisis Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers the Adrenal Crisis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Adrenal Crisis Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Adrenal Crisis key players involved in developing targeted therapeutics.

 

Major market players include Antares Pharma, Eton Pharmaceuticals, among others.

 

Pipeline Development Activities

The report covers collaborations, acquisitions, mergers, licensing, and patent details for Adrenal Crisis emerging therapies.

 

In June 2021, Eton Pharmaceuticals announced that it had acquired US and Canadian rights to Crossject’s Zeneo hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.

 

Under the terms of the agreement, Crossject will receive development and regulatory milestone payments from Eton of up to USD 5.0 million, commercial milestones of up to USD 6.0 million, and a 10% royalty on net sales of the product. Crossject will be responsible for the management and expense of development, clinical, and manufacturing activities, and Eton will be responsible for all regulatory and commercial activities.

Reimbursement Scenario in Adrenal Crisis

Proactively approaching reimbursement can positively impact both during the early stages of product development and after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with better market access can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Adrenal Crisis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Adrenal Crisis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Adrenal Crisis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of the Adrenal Crisis, explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight has been provided into the Adrenal Crisis epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Adrenal Crisis is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Adrenal Crisis market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Adrenal Crisis market.

Report Highlights

  • In the coming years, the Adrenal Crisis market is set to change due to the rising awareness of the disease, the development of diagnostic techniques, and the favorable environment from regulators for innovative first-in-class curative drugs that are likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Adrenal Crisis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Adrenal Crisis. The launch of emerging therapies will significantly impact the Adrenal Crisis market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Adrenal Crisis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Adrenal Crisis Pipeline Analysis
  • Adrenal Crisis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Adrenal Crisis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Adrenal Crisis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Adrenal Crisis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the Adrenal Crisis Market share (%) distribution in 2019, and how would it look in 2032?
  • What would the Adrenal Crisis total market size and market size by therapies across the 7MM forecast period (2019–2032) be?
  • What are the key findings of the market across 7MM, and which country will have the largest Adrenal Crisis market size during the forecast period (2019–2032)?
  • At what CAGR the Adrenal Crisis market is expected to grow by 7MM during the forecast period (2019–2032)?
  • What would be the Adrenal Crisis market outlook across the 7MM during the forecast period (2019–2032)?
  • What would be the Adrenal Crisis market growth till 2032, and what will be the resultant market Size in the year 2032?

 

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of Adrenal Crisis?
  • What is the historical Adrenal Crisis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Adrenal Crisis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population for Adrenal Crisis?
  • Out of all 7MM countries, which country would have the largest prevalent population of Adrenal Crisis during the forecast period (2019–2032)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2019–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for Adrenal Crisis treatment and the approved therapy?
  • What are the current treatment guidelines for treating Adrenal Crisis in the US, Europe, and Japan?
  • What is the Adrenal Crisis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Adrenal Crisis?
  • How many therapies are developed by each company for the treatment of Adrenal Crisis?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Adrenal Crisis?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Adrenal Crisis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Adrenal Crisis and its status?
  • What key designations have been granted for the emerging therapies for Adrenal Crisis?
  • What are the global historical and forecasted markets for Adrenal Crisis?

Reasons to buy

  • The report will help develop business strategies by understanding trends shaping and driving the Adrenal Crisis market.
  • To understand the future market competition in the Adrenal Crisis market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Adrenal Crisis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Adrenal Crisis market.
  • To understand the future market competition in the Adrenal Crisis market.

1. Key Insights

2. Report Introduction

3. Adrenal Crisis Market Overview at a Glance

3.1. Market Share (%) Distribution of Adrenal Crisis in 2019

3.2. Market Share (%) Distribution of Adrenal Crisis in 2032

4. Executive Summary of Adrenal Crisis

5. Disease Background and Overview

5.1. Introduction

5.2. Clinical Presentation of Adrenal Crisis

5.3. Etiology

5.4. Pathogenesis

5.5. Diagnosis

5.6. Diagnostic Guidelines

5.6.1. NHS UK

5.6.2. Society for Endocrinology

5.6.3. Japan Endocrine Society clinical practice guideline

5.6.4. SEEN guidelines for the management and prevention of Adrenal crisis

5.7. Differential Diagnosis

5.8. Prognosis

5.9. Prevention

5.10. Treatment and Management

5.10.1. Treatment Algorithm

5.11. Treatment Guidelines

5.11.1. NHS UK

5.11.2. Britain’s Society for Endocrinology

5.11.3. Japan Endocrine Society clinical practice guideline

5.11.4. SEEN guidelines for the management and prevention of Adrenal crisis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Population of Adrenal Crisis

6.3. Assumptions and Rationale

6.4. The United States

6.4.1. Total Diagnosed Prevalent Cases of Adrenal Crisis in the United States

6.4.2. Gender-specific Cases of Adrenal Crisis in the United States

6.4.3. Age-specific Cases of Adrenal Crisis in the United States

6.5. EU-5

6.5.1. Total Prevalent Cases of Adrenal Crisis in EU-5

6.5.2. Gender-specific Cases of Adrenal Crisis in EU-5

6.5.3. Age-specific Cases of Adrenal Crisis in EU-5

6.6. Japan

6.6.1. Total Diagnosed Prevalent Cases of Adrenal Crisis in Japan

6.6.2. Gender-specific Cases of Adrenal Crisis in Japan

6.6.3. Age-specific Cases of Adrenal Crisis in Japan

7. Patient Journey

8. Emerging Therapies

8.1. Key Cross Competition

8.2. ATRS-1902: Antares Pharma

8.2.1. Drug Description

8.2.2. Regulatory Milestones

8.2.3. Other Development Activities

8.2.4. Safety and Efficacy

8.2.5. Product Profile

8.3. Zeneo: Eton Pharmaceuticals

8.3.1. Drug Description

8.3.2. Other Development Activities

8.3.3. Product Profile

9. Adrenal Crisis: Seven Major Market Analysis

9.1. Key Findings

9.2. Market Size of Adrenal Crisis in the 7MM

9.3. Market Outlook

9.4. United States Market Size

9.4.1. Total Market Size of Adrenal Crisis in the United States

9.4.2. Market Size of Adrenal Crisis by Therapies

9.5. EU-5 Market

9.5.1. Total Market Size of Adrenal Crisis in EU-5

9.5.2. Germany

9.5.3. France

9.5.4. Italy

9.5.5. Spain

9.5.6. United Kingdom

9.6. Japan

9.6.1. Total Market Size of Adrenal Crisis in Japan

9.6.2. Market Size of Adrenal Crisis by Therapies in Japan

10. SWOT Analysis

11. Unmet Needs

12. KOL Views

13. Market Access and Reimbursement

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Table

Table 1: Summary of Adrenal Crisis, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Acute treatment of the adrenal crisis

Table 3: Total Prevalent Population of Adrenal Crisis in 7MM (2019–2032)

Table 4: Total Prevalent Cases of Adrenal Crisis in the United States (2019–2032)

Table 5: Gender-specific Cases of Adrenal Crisis in the United States (2019–2032)

Table 6: Age-specific Cases of Adrenal Crisis in the United States (2019–2032)

Table 7: Total Diagnosed Prevalent Cases of Adrenal Crisis in EU5 (2019–2032)

Table 8: Gender-specific Cases of Adrenal Crisis in EU-5 (2019–2032)

Table 9: Age-specific Cases of Adrenal Crisis in EU-5 (2019–2032)

Table 10: Total Prevalent Cases of Adrenal Crisis in Japan (2019–2032)

Table 11: Gender-specific Cases of Adrenal Crisis in Japan (2019–2032)

Table 12: Age-specific Cases of Adrenal Crisis in Japan (2019–2032)

Table 13: Seven Major Market Size of Adrenal Crisis in USD million (2019–2032)

Table 14: The US Market Size of Adrenal Crisis in USD million (2019–2032)

Table 15: The US Market Size of Adrenal Crisis by Therapies in USD million (2019–2032)

Table 16: EU-5 Market Size of Adrenal Crisis in USD million (2019–2032)

Table 17: Germany Market Size of Adrenal Crisis by Therapies in USD million (2019–2032)

Table 18: France Market Size of Adrenal Crisis by Therapies in USD million (2019–2032)

Table 19: Italy Market Size of Adrenal Crisis by Therapies in USD million (2019–2032)

Table 20: Spain Market Size of Adrenal Crisis by Therapies in USD million (2019–2032)

Table 21: The UK Market Size of Adrenal Crisis by Therapies in USD million (2019–2032)

Table 22: Japan Market Size of Adrenal Crisis in USD million (2019–2032)

Table 23: Japan Market Size of Adrenal Crisis by Therapies in USD million (2019–2032)

List of Figures

Figure 1: Clinical Presentation in Adrenal Crisis

Figure 2: Pathogenesis of Adrenal Crisis

Figure 3: Diagnostic criteria of Adrenal crisis

Figure 4: Differential Diagnosis of Adrenal Crisis

Figure 5: Treatment Algorithm for Adrenal Crisis

Figure 6: Summary of NHS Guidelines for Adrenal Crisis

Figure 7: Total Prevalent Population of Adrenal Crisis in the 7MM (2019–2032)

Figure 8: Total Prevalent Cases of Adrenal Crisis in the US (2019–2032)

Figure 9: Gender-specific Cases of Adrenal Crisis in the United States (2019–2032)

Figure 10: Age-specific Cases of Adrenal Crisis in the United States (2019–2032)

Figure 11: Total Diagnosed Prevalent Cases of Adrenal Crisis in EU5 (2019–2032)

Figure 12: Gender-specific Cases of Adrenal Crisis in EU-5 (2019–2032)

Figure 13: Age-specific Cases of Adrenal Crisis in EU-5 (2019–2032)

Figure 14: Total Prevalent Cases of Adrenal Crisis in Japan (2019–2032)

Figure 15: Gender-specific Cases of Adrenal Crisis in Japan (2019–2032)

Figure 16: Age-specific Cases of Adrenal Crisis in Japan (2019–2032)

Figure 17: Seven Major Market Size of Adrenal Crisis in USD million (2019–2032)

Figure 18: The US Market Size of Adrenal Crisis in USD million (2019–2032)

Figure 19: The US Market Size of Adrenal Crisis by Therapies (2019–2032)

Figure 20: EU-5 Market Size of Adrenal Crisis in USD million (2019–2032)

Figure 21: Germany Market Size of Adrenal Crisis by Therapies (2019–2032)

Figure 22: France Market Size of Adrenal Crisis by Therapies (2019–2032)

Figure 23: Italy Market Size of Adrenal Crisis by Therapies (2019–2032)

Figure 24: Spain Market Size of Adrenal Crisis by Therapies (2019–2032)

Figure 25: The United Kingdom Market Size of Adrenal Crisis by Therapies (2019–2032)

Figure 26: Japan Market Size of Adrenal Crisis in USD million (2019–2032)

Figure 27: Japan Market Size of Adrenal Crisis by Therapies (2019–2032)

Eton Pharmaceuticals

Antares Pharma

Forward to Friend

Need A Quote